Synergy Pharmaceuticals Incorporated (SGYP)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.01 / 0.04
Exchange NASDAQ
Div & Yield N.A. (N.A)
First Week Of SGYP December 15th Options Trading

First Week Of SGYP December 15th Options Trading

Investors in Synergy Pharmaceuticals Inc saw new options become available this week, for the December 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGYP options chain for the new December 15th contracts and identified one put and one call contract of particular interest.

Don't Panic About Biotech

Don't Panic About Biotech

Diversification is absolutely critical when investing in this sector.

Synergy Pharmaceuticals Presents Results From Study Examining Patient And Physician Perceptions And Experiences With Irritable Bowel Syndrome With Constipation (IBS-C)

Synergy Pharmaceuticals Presents Results From Study Examining Patient And Physician Perceptions And Experiences With Irritable Bowel Syndrome With Constipation (IBS-C)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today new findings highlighting the frustration of patients suffering from irritable bowel syndrome with constipation (IBS-C) and the perceptions of healthcare providers...

Synergy Pharmaceuticals To Highlight New Data For TRULANCE® (Plecanatide) At The World Congress Of Gastroenterology (WCOG) At American College Of Gastroenterology (ACG)

Synergy Pharmaceuticals To Highlight New Data For TRULANCE® (Plecanatide) At The World Congress Of Gastroenterology (WCOG) At American College Of Gastroenterology (ACG)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that the company will present two abstracts, including Phase 3 studies evaluating TRULANCE ® (plecanatide) for the treatment of adults with irritable bowel...

Trio of Stocks Set to Ride Small-Cap Train

Trio of Stocks Set to Ride Small-Cap Train

I continue to like these 3 names.

Drug Approvals Don't Always Translate Into Stock Gains: 3 Biotech Examples

Drug Approvals Don't Always Translate Into Stock Gains: 3 Biotech Examples

Winning FDA approval isn't always a win.

First Week Of November 17th Options Trading For Synergy Pharmaceuticals (SGYP)

First Week Of November 17th Options Trading For Synergy Pharmaceuticals (SGYP)

Investors in Synergy Pharmaceuticals Inc saw new options become available this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGYP options chain for the new November 17th contracts and identified one put and one call contract of particular interest.

Winning FDA Approval Isn't Always a Win

Winning FDA Approval Isn't Always a Win

The experiences of three biotechs show how drug approvals don't always translate into stock gains.

Will Allergan's Deal With Tribe Hold Up?

Will Allergan's Deal With Tribe Hold Up?

Answering questions from the biotech mailbag.

SGYP January 2020 Options Begin Trading

SGYP January 2020 Options Begin Trading

Investors in Synergy Pharmaceuticals Inc saw new options become available today, for the January 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 858 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

2 Small Biotechs Under $5 May Be Bargains

2 Small Biotechs Under $5 May Be Bargains

T2 Biosystems and Synergy Pharmaceuticals offer promising prospects at reasonable prices.

Insiders Now Seeing Red With SGYP At New 52-Week Low

Insiders Now Seeing Red With SGYP At New 52-Week Low

In trading on Friday, shares of Synergy Pharmaceuticals Inc touched a new 52-week low of $2.71/share. That's a $4.44 share price drop, or -62.10% decline from the 52-week high of $7.15 set back on 01/31/2017.

CORRECTING and REPLACING Synergy Pharmaceuticals to Present at Upcoming September Investor Conferences

CORRECTING and REPLACING Synergy Pharmaceuticals to Present at Upcoming September Investor Conferences

In the release dated September 6, 2017, the presentation date and time for the Cantor Fitzgerald Global Healthcare Conference should be changed to Wednesday, September 27, 2017 at 9:45 a.

Synergy Pharmaceuticals Secures $300 Million Debt Financing

Synergy Pharmaceuticals Secures $300 Million Debt Financing

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), announced today that the Company has closed on a $300 million debt financing structured as senior secured loans from CRG LP, a healthcare focused investment firm, and its lender...

SGYP: Insiders vs. Shorts

SGYP: Insiders vs. Shorts

The most recent short interest data was recently released for the 08/15/2017 settlement date, and Synergy Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 10.03 "days to cover" versus the median component at 5.20. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

First Week of SGYP April 2018 Options Trading

First Week of SGYP April 2018 Options Trading

Investors in Synergy Pharmaceuticals Inc saw new options begin trading this week, for the April 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Synergy Pharmaceuticals Reports Second Quarter 2017 Financial Results And Business Update

Synergy Pharmaceuticals Reports Second Quarter 2017 Financial Results And Business Update

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for...

Resist All the Dow 22K Hoopla: Cramer's 'Mad Money' Recap (Wednesday 8/2/17)

Resist All the Dow 22K Hoopla: Cramer's 'Mad Money' Recap (Wednesday 8/2/17)

Jim Cramer says investors should step away from these near-term shenanigans and focus on the fundamentals.

3 Biotech Stocks on Readers' Minds

3 Biotech Stocks on Readers' Minds

We answer questions about BioDelivery Sciences, Dynavax Technologies and Synergy Pharmaceuticals.

Biotech Stocks Finally Stage Breakthrough

Biotech Stocks Finally Stage Breakthrough

The sector decisively has pushed through upward resistance levels in place for many months.

First Week of SGYP August 18th Options Trading

Investors in Synergy Pharmaceuticals Inc saw new options become available this week, for the August 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGYP options chain for the new August 18th contracts and identified one put and one call contract of particular interest.

Comcast, Synergy Pharmaceuticals, Chipotle, Blackstone Group: 'Mad Money' Lightning Round

Comcast, Synergy Pharmaceuticals, Chipotle, Blackstone Group: 'Mad Money' Lightning Round

Jim Cramer is bullish on Comcast, Synergy Pharmaceuticals, Chipotle, and Blackstone Group, but he's bearish on Sierra Wireless.

Go Inside Amazon's Disruptive Deal for Whole Foods: Cramer's 'Mad Money' Recap (Friday 6/16/17)

Go Inside Amazon's Disruptive Deal for Whole Foods: Cramer's 'Mad Money' Recap (Friday 6/16/17)

Amazon wants to entertain and clothe -- and now feed -- every American. Cramer names the winners and the losers in this deal.

Non-FANG Stocks May Finally Get Some Love

Non-FANG Stocks May Finally Get Some Love

Tech meltdown provides an opportunity for rotation into undervalued sectors.

Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals

Biotech Movers: Shire Falls on Stem Cell Program Transfer; Calithera, Synergy Up on FDA Approvals

Plus more from the biotechnology world on Wednesday, June 7.

3 Beaten-Down Biotechs That Should Head Up

3 Beaten-Down Biotechs That Should Head Up

Synergy Pharmaceuticals, Trevena and Egalet seem to have worst-case scenarios priced into them.

Here's the Volatile Biotech Stock One Analyst Thinks Could Boom 175%

Here's the Volatile Biotech Stock One Analyst Thinks Could Boom 175%

Synergy Pharmaceuticals, Bluebird Bio and DBV Technologies were among the biotech stock movers in early trading on Friday.

New 52-Week Low Could Prompt More Insider Buying At SGYP

In trading on Wednesday, shares of Synergy Pharmaceuticals Inc touched a new 52-week low of $3.34/share. That's a $3.81 share price drop, or -53.29% decline from the 52-week high of $7.15 set back on 01/31/2017.

SGYP: Insiders vs. Shorts

The most recent short interest data was recently released for the 05/15/2017 settlement date, and Synergy Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 10.18 "days to cover" versus the median component at 4.71. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.